SI3535397T1 - Ligandi alfa-V beta-6 integrina in njihove uporabe - Google Patents
Ligandi alfa-V beta-6 integrina in njihove uporabeInfo
- Publication number
- SI3535397T1 SI3535397T1 SI201731066T SI201731066T SI3535397T1 SI 3535397 T1 SI3535397 T1 SI 3535397T1 SI 201731066 T SI201731066 T SI 201731066T SI 201731066 T SI201731066 T SI 201731066T SI 3535397 T1 SI3535397 T1 SI 3535397T1
- Authority
- SI
- Slovenia
- Prior art keywords
- beta
- alpha
- integrin ligands
- integrin
- ligands
- Prior art date
Links
- 108010021309 integrin beta6 Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662415752P | 2016-11-01 | 2016-11-01 | |
EP17867252.3A EP3535397B1 (en) | 2016-11-01 | 2017-11-01 | Alpha-v beta-6 integrin ligands and uses thereof |
PCT/US2017/059550 WO2018085415A1 (en) | 2016-11-01 | 2017-11-01 | Alpha-v beta-6 integrin ligands and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3535397T1 true SI3535397T1 (sl) | 2022-04-29 |
Family
ID=62076333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201731066T SI3535397T1 (sl) | 2016-11-01 | 2017-11-01 | Ligandi alfa-V beta-6 integrina in njihove uporabe |
Country Status (22)
Country | Link |
---|---|
US (2) | US11180529B2 (sl) |
EP (2) | EP3535397B1 (sl) |
JP (3) | JP7291624B2 (sl) |
KR (1) | KR102634762B1 (sl) |
CN (2) | CN117285626A (sl) |
AU (2) | AU2017354041B2 (sl) |
BR (1) | BR112019008965A2 (sl) |
CA (1) | CA3039618A1 (sl) |
DK (1) | DK3535397T3 (sl) |
EA (1) | EA201991102A1 (sl) |
ES (1) | ES2906109T3 (sl) |
HR (1) | HRP20220181T1 (sl) |
IL (2) | IL305158A (sl) |
JO (1) | JOP20190084B1 (sl) |
MX (3) | MX2019004909A (sl) |
NZ (1) | NZ751843A (sl) |
PL (1) | PL3535397T3 (sl) |
SA (1) | SA519401709B1 (sl) |
SI (1) | SI3535397T1 (sl) |
TW (1) | TWI776821B (sl) |
WO (1) | WO2018085415A1 (sl) |
ZA (2) | ZA201901905B (sl) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ751843A (en) * | 2016-11-01 | 2025-05-02 | Arrowhead Pharmaceuticals Inc | Alpha-v beta-6 integrin ligands and uses thereof |
IL297530B2 (en) | 2017-02-28 | 2025-04-01 | Morphic Therapeutic Inc | (Alpha–V)(beta–6) integrin inhibitors |
AU2018227417B2 (en) | 2017-02-28 | 2021-12-23 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
PE20200746A1 (es) | 2017-07-06 | 2020-07-24 | Arrowhead Pharmaceuticals Inc | AGENTES DE iARN PARA LA INHIBICION DE LA EXPRESION DE ALFA-ENAC Y METODOS DE USO |
EP4086254B1 (en) | 2018-08-29 | 2024-12-18 | Morphic Therapeutic, Inc. | Integrin inhibitors |
KR102663798B1 (ko) | 2019-06-25 | 2024-05-03 | 주식회사 엘지에너지솔루션 | 배터리 시스템 |
CA3189071A1 (en) * | 2020-09-11 | 2022-03-17 | Xiaokai Li | Skeletal muscle delivery platforms and methods of use |
CA3189081A1 (en) * | 2020-09-11 | 2022-03-17 | Xiaokai Li | Integrin targeting ligands and uses thereof |
MX2023002853A (es) | 2020-09-11 | 2023-03-31 | Arrowhead Pharmaceuticals Inc | Agentes de arni para inhibir la expresion de dux4, composiciones de dichos agentes, y metodos de uso. |
WO2022251394A1 (en) | 2021-05-28 | 2022-12-01 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of mucin 5ac (muc5ac), compositions thereof, and methods of use |
EP4547683A2 (en) | 2022-06-30 | 2025-05-07 | Alnylam Pharmaceuticals, Inc. | Cyclic-disulfide modified phosphate based oligonucleotide prodrugs |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
DE19929410A1 (de) * | 1999-06-26 | 2000-12-28 | Merck Patent Gmbh | Inhibitoren des Integrins avß6 |
JP2003530871A (ja) * | 2000-04-21 | 2003-10-21 | アムジエン・インコーポレーテツド | インテグリン/接着因子アンタゴニスト |
DE10118550A1 (de) * | 2001-04-14 | 2002-10-17 | Merck Patent Gmbh | Liganden des Integrins alpha¶nu¶beta¶6¶ |
GB0520068D0 (en) | 2005-10-03 | 2005-11-09 | Cancer Res Technology | av peptide ligand |
BRPI0715141A2 (pt) * | 2006-08-03 | 2013-06-04 | Astrazeneca Ab | agente de ligaÇço alvejante, anticorpo isolado, fragmento de anticorpo isolado, molÉcula de Ácido nucleico, vetor, cÉlula hospedeira, mÉtodos para produzir um agente de ligaÇço alvejado, para produzir um anticorpo, para produzir um fragmento de anticorpo, para tratar um tumor maligno em um animal, para tratar inflamaÇço, e para inibir a interaÇço de alfabeta6 com seu ligando, e, conjugado |
AR066984A1 (es) | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
EP2221334B1 (en) | 2007-11-28 | 2016-12-28 | FUJIFILM Corporation | Method for chemically modifying biopolymer and polypeptide |
AU2011333666B2 (en) * | 2010-11-26 | 2017-02-02 | Molecular Partners Ag | Improved capping modules for designed ankyrin repeat proteins |
CN105017420B (zh) * | 2012-02-17 | 2019-05-28 | 西雅图基因公司 | 针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症 |
EP3131566B1 (en) * | 2014-04-15 | 2022-10-05 | The Regents of the University of California | Bi-terminal pegylated integrin-binding peptides and methods of use thereof |
US10073109B2 (en) * | 2015-04-06 | 2018-09-11 | The Board Of Regents Of The University Of Oklahoma | Phages of biomarker capture and methods of use |
EP3130912B1 (de) | 2015-08-14 | 2017-06-28 | Sick Ag | Verfahren zur bestimmung der konzentration einer gaskomponente und spektrometer dafür |
JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
NZ751843A (en) * | 2016-11-01 | 2025-05-02 | Arrowhead Pharmaceuticals Inc | Alpha-v beta-6 integrin ligands and uses thereof |
-
2017
- 2017-11-01 NZ NZ751843A patent/NZ751843A/en unknown
- 2017-11-01 JO JOP/2019/0084A patent/JOP20190084B1/ar active
- 2017-11-01 WO PCT/US2017/059550 patent/WO2018085415A1/en active Application Filing
- 2017-11-01 KR KR1020197012274A patent/KR102634762B1/ko active Active
- 2017-11-01 CN CN202311057967.9A patent/CN117285626A/zh active Pending
- 2017-11-01 EP EP17867252.3A patent/EP3535397B1/en active Active
- 2017-11-01 CN CN201780068077.4A patent/CN109952376B/zh active Active
- 2017-11-01 CA CA3039618A patent/CA3039618A1/en active Pending
- 2017-11-01 TW TW106137824A patent/TWI776821B/zh active
- 2017-11-01 EP EP21202340.2A patent/EP3981780A1/en active Pending
- 2017-11-01 BR BR112019008965A patent/BR112019008965A2/pt active Search and Examination
- 2017-11-01 ES ES17867252T patent/ES2906109T3/es active Active
- 2017-11-01 PL PL17867252T patent/PL3535397T3/pl unknown
- 2017-11-01 IL IL305158A patent/IL305158A/en unknown
- 2017-11-01 HR HRP20220181TT patent/HRP20220181T1/hr unknown
- 2017-11-01 EA EA201991102A patent/EA201991102A1/ru unknown
- 2017-11-01 IL IL266343A patent/IL266343B2/en unknown
- 2017-11-01 JP JP2019522676A patent/JP7291624B2/ja active Active
- 2017-11-01 AU AU2017354041A patent/AU2017354041B2/en active Active
- 2017-11-01 DK DK17867252.3T patent/DK3535397T3/da active
- 2017-11-01 SI SI201731066T patent/SI3535397T1/sl unknown
- 2017-11-01 MX MX2019004909A patent/MX2019004909A/es unknown
-
2019
- 2019-03-27 ZA ZA2019/01905A patent/ZA201901905B/en unknown
- 2019-04-26 MX MX2023007051A patent/MX2023007051A/es unknown
- 2019-04-26 MX MX2023007046A patent/MX2023007046A/es unknown
- 2019-04-30 US US16/399,073 patent/US11180529B2/en active Active
- 2019-05-01 SA SA519401709A patent/SA519401709B1/ar unknown
-
2021
- 2021-10-14 US US17/501,486 patent/US12173086B2/en active Active
-
2022
- 2022-03-18 ZA ZA2022/03240A patent/ZA202203240B/en unknown
-
2023
- 2023-06-02 JP JP2023091857A patent/JP2023105046A/ja not_active Withdrawn
-
2024
- 2024-04-24 AU AU2024202695A patent/AU2024202695A1/en active Pending
-
2025
- 2025-05-02 JP JP2025076681A patent/JP2025107348A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202203240B (en) | Alpha-v beta-6 integrin ligands and uses thereof | |
SG11202002967SA (en) | Integrin ligands and uses thereof | |
IL272330A (en) | Anti-CD47 antibodies and uses thereof | |
SG11201808632YA (en) | Anti-pacap antibodies and uses thereof | |
SG10202007176TA (en) | Anti-cd47 antibodies and uses thereof | |
IL248947B (en) | Antagonists for a4b7 integrin thioether peptide | |
ZA201901935B (en) | Anti-il-33 antibodies and uses thereof | |
IL262010A (en) | Anti-complement factor bb antibodies and their uses | |
IL266049A (en) | Antibodies against o1 and their uses | |
IL266082A (en) | Anti-chikv antibodies and their use | |
IL264417A (en) | Anti-o2 antibodies and their uses | |
IL258863A (en) | Integrin-binding peptides and their use | |
GB201603311D0 (en) | New uses and methods | |
GB2548839B (en) | New uses and methods | |
EP3279378A4 (en) | Airbag-use woven fabric and airbag | |
SG11201912432VA (en) | Emm-23 materials and processes and uses thereof | |
GB201615254D0 (en) | Novel Ligand and use thereof | |
SI3350222T1 (sl) | Ligandi za integrin avbeta6, sinteza in uporaba le-teh | |
HK40014552A (en) | Alpha-v beta-6 integrin ligands and uses thereof | |
SG11202005282VA (en) | Emm-31 materials and processes and uses thereof | |
HK40033843A (zh) | 整聯蛋白配體及其用途 | |
GB201710941D0 (en) | Ligands and catalysts | |
GB2549557B (en) | Bucket-tidy and method of organising items held within a bucket | |
GB201619935D0 (en) | Heterogenneous catalyst and uses thereof |